Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial
Publication
, Journal Article
Juraska, M; Early, AM; Li, L; Schaffner, SF; Lievens, M; Khorgade, A; Simpkins, B; Hejazi, NS; Benkeser, D; Wang, Q; Mercer, LD; Adjei, S ...
Published in: The Lancet Infectious Diseases
September 2024
Duke Scholars
Published In
The Lancet Infectious Diseases
DOI
ISSN
1473-3099
Publication Date
September 2024
Volume
24
Issue
9
Start / End Page
1025 / 1036
Publisher
Elsevier BV
Related Subject Headings
- Microbiology
- 4202 Epidemiology
- 3207 Medical microbiology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1108 Medical Microbiology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Juraska, M., Early, A. M., Li, L., Schaffner, S. F., Lievens, M., Khorgade, A., … Neafsey, D. E. (2024). Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. The Lancet Infectious Diseases, 24(9), 1025–1036. https://doi.org/10.1016/s1473-3099(24)00179-8
Juraska, Michal, Angela M. Early, Li Li, Stephen F. Schaffner, Marc Lievens, Akanksha Khorgade, Brian Simpkins, et al. “Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial.” The Lancet Infectious Diseases 24, no. 9 (September 2024): 1025–36. https://doi.org/10.1016/s1473-3099(24)00179-8.
Juraska M, Early AM, Li L, Schaffner SF, Lievens M, Khorgade A, et al. Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. The Lancet Infectious Diseases. 2024 Sep;24(9):1025–36.
Juraska, Michal, et al. “Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial.” The Lancet Infectious Diseases, vol. 24, no. 9, Elsevier BV, Sept. 2024, pp. 1025–36. Crossref, doi:10.1016/s1473-3099(24)00179-8.
Juraska M, Early AM, Li L, Schaffner SF, Lievens M, Khorgade A, Simpkins B, Hejazi NS, Benkeser D, Wang Q, Mercer LD, Adjei S, Agbenyega T, Anderson S, Ansong D, Bii DK, Buabeng PBY, English S, Fitzgerald N, Grimsby J, Kariuki SK, Otieno K, Roman F, Samuels AM, Westercamp N, Ockenhouse CF, Ofori-Anyinam O, Lee CK, MacInnis BL, Wirth DF, Gilbert PB, Neafsey DE. Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. The Lancet Infectious Diseases. Elsevier BV; 2024 Sep;24(9):1025–1036.
Published In
The Lancet Infectious Diseases
DOI
ISSN
1473-3099
Publication Date
September 2024
Volume
24
Issue
9
Start / End Page
1025 / 1036
Publisher
Elsevier BV
Related Subject Headings
- Microbiology
- 4202 Epidemiology
- 3207 Medical microbiology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1108 Medical Microbiology
- 1103 Clinical Sciences